Research programme: chimeric antigen receptor natural killer cell therapies - CytomX Therapeutics/MD Anderson Cancer CenterAlternative Names: ProCAR NK cell therapies; ProCAR-NK therapies
Latest Information Update: 10 Nov 2015
At a glance
- Originator CytomX Therapeutics; University of Texas M. D. Anderson Cancer Center
- Class Cell therapies; Immunoconjugates
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer